Organization · Government VC
Taiwania Capital
Taiwania Capital is a government-backed venture capital firm based in Taiwan, focused on investing in technology and biotech startups in Taiwan and the US. It aims to foster entrepreneurial innovation and boost Taiwan's economic growth.
Overview
What Taiwania Capital does
What Taiwania Capital is
Taiwania Capital is a government-backed venture capital firm based in Taiwan, focused on investing in technology and biotech startups in Taiwan and the US. It aims to foster entrepreneurial innovation and boost Taiwan's economic growth.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Government VC
- Founded
- Founded in 2017
- Approximate age
- About 9 years
- Structured capabilities
- Funder
- Last reviewed
- February 28, 2026
Official channels
Find Taiwania Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Taiwania Capital as a funder
Investment thesis
Connecting Taiwan's robust tech and biotech ecosystems with global innovations. Invests in companies with the potential to become leaders in industry transformation across enterprise software, AI, biotech, and medical technology.
Focus narrative
Enterprise software, autonomous systems, AI, IoT, information security, pharmaceutical R&D, gene, biotechnology, and medical technology. Series A ($31.6M avg) and Series B ($37M avg) primarily, with Seed. Taiwan, US, Japan, Southeast Asia, and Central/Eastern Europe.
Value beyond capital
Access to Taiwan's tech and biotech innovation ecosystem. Global networks across US, Japan, Southeast Asia. Strategic partnerships for market expansion. Track record with multiple unicorn-scale acquisitions. Sector expertise in enterprise software, AI, IoT, and life sciences.
Terms and economics
- Typical check
- $5,770,000–$37,000,000
- Sweet spot
- $31,600,000
Focus and fit
- Stages
- Seed · Series A · Series B
- Sectors
- AI · SaaS · Fintech · Healthcare · Biotech · Cybersecurity · Robotics · Semiconductor Design · Generative AI · Ai Infrastructure · Digital Health · Medical Devices · Drug Discovery · Genomics
- Regions
- Asia · Cee · Global · Jp · North America · Southeast Asia · Tw · United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 75
- Investments in the last 12 months
- 4
- Last recorded investment
- January 28, 2026
- Recorded notable exits
- EirGenix, C4 Therapeutics, Viracta, AEye, and Ambiq
Portfolio context
75 companies, 14 IPOs, 4 acquisitions. Notable: C4 Therapeutics ($3.3B), Ambiq (NYSE, $409M), Viracta ($320M), AEye ($1.5B), EirGenix ($1.11B). Recent: Decube (Jan 2026), Resemble AI, Arris Composites. Multiple specialized funds: Buffalo (tech/IoT), Life Sciences (biotech), CEE Fund (semiconductor, fintech, EV).
Common questions
What to know about Taiwania Capital
Upseed classifies Taiwania Capital under the Government VC organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
February 28, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.